Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ C5009948/?report=reader!5009948!27683537     free     free     free       EJIFCC 2016 ; 27 (3): 238-52 Nephropedia Template TP {{tp|p=27683537|t=2016. ST2 and Galectin-3: Ready for Prime Time?|pdf=|usr=}}{{27683537}} gab.com Text ST2 and Galectin-3: Ready for Prime Time JO: EJIFCC http://www.kidney.de/pget.php?&tw=1&pmid=27683537 #FOAvip ST2 and galectin-3 are emerging biomarkers in the field of heart failure and have been extensively studied, and that whether they provide additional prognostic value on top of the clinical models and the gold standard in HF, (NT-pro)BNP. Our aim was to provide a comprehensive review of these emerging HF-related biomarkers in chronic, acute and incident heart failure. Regardless of the type of heart failure, both biomarkers seem to have an additional effect on top of the clinical model including natriuretic peptides. Strategies that combine multiple biomarkers may ultimately prove to be beneficial in the guidance of HF therapy in the future. However, additional prognostic value appears to be limited, and what we need is to prospectively test the consistent observations, which then might lead to the implementation of ST2 and galectin-3 in heart failure algorithms. Twit Text FOAVip ST2 and Galectin-3: Ready for Prime Time ????EJIFCC http://www.kidney.de/pget.php?&tw=1&pmid=27683537 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27683537 #FOAvip English Wikipedia <ref>{{Cite pmid|27683537}}</ref> ST2 and Galectin-3: Ready for Prime Time? #MMPMID27683537 Meijers WC; van der Velde AR; de Boer RA EJIFCC 2016[Jul]; 27 (3): 238-52 PMID27683537show ga ST2 and galectin-3 are emerging biomarkers in the field of heart failure and have been extensively studied, and that whether they provide additional prognostic value on top of the clinical models and the gold standard in HF, (NT-pro)BNP. Our aim was to provide a comprehensive review of these emerging HF-related biomarkers in chronic, acute and incident heart failure. Regardless of the type of heart failure, both biomarkers seem to have an additional effect on top of the clinical model including natriuretic peptides. Strategies that combine multiple biomarkers may ultimately prove to be beneficial in the guidance of HF therapy in the future. However, additional prognostic value appears to be limited, and what we need is to prospectively test the consistent observations, which then might lead to the implementation of ST2 and galectin-3 in heart failure algorithms. äST2 and Galectin-3: Ready for Prime Time?(epmc).pdf DeepDyve Pubget Overpricing